Novartis Stock Earnings Estimates Raised by Zacks Research

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research boosted their FY2026 earnings per share estimates for Novartis in a research report issued on Tuesday, November 10th. Zacks Research analyst Team now forecasts that the company will earn $9.06 per share for the year, up from their prior estimate of $8.83. The consensus estimate for Novartis’ current full-year earnings is $9.04 per share. Zacks Research also issued estimates for Novartis’ Q4 2026 earnings at $2.20 EPS, Q1 2027 earnings at $2.29 EPS, Q2 2027 earnings at $2.53 EPS, Q3 2027 earnings at $2.57 EPS, Q4 2027 earnings at $2.53 EPS, FY2027 earnings at $9.91 EPS, Q1 2028 earnings at $2.45 EPS, Q2 2028 earnings at $2.70 EPS and Q3 2028 earnings at $2.73 EPS.

Several other brokerages have also recently weighed in on NVS. Citigroup reiterated a “buy” rating on shares of Novartis in a research note on Wednesday, July 22nd. Morgan Stanley restated an “overweight” rating and set a $163.00 target price on shares of Novartis in a research report on Wednesday, October 28th. Sanford C. Bernstein reaffirmed a “neutral” rating on shares of Novartis in a report on Wednesday, July 22nd. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Novartis in a research report on Wednesday, October 28th. Finally, Bank of America reiterated a “buy” rating on shares of Novartis in a research note on Tuesday, September 8th. Six research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Novartis currently has an average rating of “Hold” and an average price target of $152.25.

Novartis Trading Down 0.2%

Novartis stock opened at $163.28 on Wednesday. Novartis has a 52-week low of $123.24 and a 52-week high of $170.46. The company has a market cap of $311.57 billion, a P/E ratio of 31.16, a P/E/G ratio of 3.01 and a beta of 0.40. The company has a quick ratio of 0.70, a current ratio of 0.88 and a debt-to-equity ratio of 0.98. The business has a 50-day simple moving average of $149.24 and a two-hundred day simple moving average of $152.44.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.53 billion. Novartis had a return on equity of 41.04% and a net margin of 18.11%. Novartis’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.25 earnings per share.

Institutional Investors Weigh In On Novartis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVS. Private Wealth Asset Management LLC lifted its holdings in Novartis by 22.8% during the third quarter. Private Wealth Asset Management LLC now owns 4,821 shares of the company’s stock valued at $687,000 after purchasing an additional 894 shares in the last quarter. Private Advisor Group LLC increased its stake in shares of Novartis by 64.2% in the third quarter. Private Advisor Group LLC now owns 47,481 shares of the company’s stock worth $6,769,000 after purchasing an additional 18,565 shares in the last quarter. Ieq Capital LLC increased its stake in shares of Novartis by 2.7% in the third quarter. Ieq Capital LLC now owns 44,526 shares of the company’s stock worth $6,348,000 after purchasing an additional 1,168 shares in the last quarter. Focus Advisor Solutions LLC raised its position in shares of Novartis by 51.9% during the 3rd quarter. Focus Advisor Solutions LLC now owns 11,396 shares of the company’s stock valued at $1,625,000 after purchasing an additional 3,892 shares during the period. Finally, Boston Partners raised its position in shares of Novartis by 36.4% during the 3rd quarter. Boston Partners now owns 73,207 shares of the company’s stock valued at $10,424,000 after purchasing an additional 19,518 shares during the period. Institutional investors own 13.12% of the company’s stock.

Novartis Company Profile

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.